Meeting
2023 ASCO Genitourinary Cancers Symposium
Preclinical evaluation of teleglenastat (CB-839) in prostate cancer.
Authors
Elaine T. Lam
University of Colorado Cancer Center Anschutz Medical Campus, Aurora, CO
Elaine T. Lam , Lih-Jen Su , Maren Salzmann-Sullivan , Steven K. Nordeen , Thomas W. Flaig
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 378)
DOI
10.1200/JCO.2023.41.6_suppl.378
Abstract #
378
Poster Bd #
N16
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
An oral androgen receptor PROTAC degrader for prostate cancer.
First Author: Taavi Neklesa
Poster
2017 Genitourinary Cancers Symposium
An oral androgen receptor PROTAC degrader for prostate cancer.
First Author: Taavi K Neklesa
Poster
2016 Genitourinary Cancers Symposium
Combined Akt and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer.
First Author: Paul Toren
Poster
2024 ASCO Genitourinary Cancers Symposium
ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).
First Author: Andrew Leonard Laccetti